284 related articles for article (PubMed ID: 26188796)
1. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.
Taha MO; Tarairah M; Zalloum H; Abu-Sheikha G
J Mol Graph Model; 2010 Jan; 28(5):383-400. PubMed ID: 19850503
[TBL] [Abstract][Full Text] [Related]
4. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
[TBL] [Abstract][Full Text] [Related]
5. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
6. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Al-Nadaf A; Abu Sheikha G; Taha MO
Bioorg Med Chem; 2010 May; 18(9):3088-115. PubMed ID: 20378363
[TBL] [Abstract][Full Text] [Related]
7. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
Gundla R; Kazemi R; Sanam R; Muttineni R; Sarma JA; Dayam R; Neamati N
J Med Chem; 2008 Jun; 51(12):3367-77. PubMed ID: 18500794
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Al-Nadaf AH; Taha MO
J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
Aboalhaija NH; Zihlif MA; Taha MO
Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606
[TBL] [Abstract][Full Text] [Related]
12. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
13. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.
Abuhamdah S; Habash M; Taha MO
J Comput Aided Mol Des; 2013 Dec; 27(12):1075-92. PubMed ID: 24338032
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors.
Brogi S; Papazafiri P; Roussis V; Tafi A
Eur J Med Chem; 2013 Sep; 67():344-51. PubMed ID: 23880359
[TBL] [Abstract][Full Text] [Related]
15. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Al-Sha'er MA; Taha MO
J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
[TBL] [Abstract][Full Text] [Related]
16. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
18. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Al-Sha'er MA; Khanfar MA; Taha MO
J Mol Model; 2014 Jan; 20(1):2080. PubMed ID: 24469103
[TBL] [Abstract][Full Text] [Related]
20. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.
Shahin R; Alqtaishat S; Taha MO
J Comput Aided Mol Des; 2012 Feb; 26(2):249-66. PubMed ID: 22167443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
